

May 21th 2021

1

# Low-field thoracic magnetic stimulation increases peripheral oxygen saturation levels in coronavirus disease (COVID-19) patients: a single-blind, sham-controlled, crossover study

Saul M Dominguez-Nicolas<sup>1,2</sup>, Elias Manjarrez<sup>3</sup>

<sup>1</sup>Centro de Investigación de Micro y Nanotecnología, Universidad Veracruzana, Calzada Ruiz Cortines 455 Boca del Rio, Veracruz 94294, México

<sup>2</sup>Facultad de Ingeniería Eléctrica y Electrónica, Universidad Veracruzana, Calzada Ruiz Cortines 455, Boca del Rio, Veracruz 94294, México

<sup>3</sup>Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla, 14 Sur 6301, Colonia San Manuel, Apartado Postal 406, CP 72570, Puebla, Puebla, México.

**Running title:** LF-ThMS improves SpO<sub>2</sub> levels in a single session

**Number of words:** Text 5661, abstract (215), introduction (625), discussion (1373)

**Number of text pages:** 25

**Number of Figures:** 4

**Number of Tables:** 3

**Trial registration:** ClinicalTrials.gov **Identifier:** NCT04895267

## \*Corresponding Authors:

### **Dr. Saul M Dominguez-Nicolas**

Centro de Investigación de Micro y Nanotecnología, Universidad Veracruzana  
Calzada Ruiz Cortines 455 Boca del Rio, Veracruz 94294, Mexico  
[saudominquez@uv.mx](mailto:saudominquez@uv.mx)

### **Dr. Elias Manjarrez**

Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla.  
14 sur 6301, Col. San Manuel A.P. 406, C.P. 72570  
Puebla, Pue., México  
Tels.: +5222-22-29-5500 Ext 7326, Fax: +5222-22-33-4511  
[eliasmanjarrez@gmail.com](mailto:eliasmanjarrez@gmail.com)  
[elias.manjarrez@correo.buap.mx](mailto:elias.manjarrez@correo.buap.mx)

**Keywords:** LF-ThMS, SARS-CoV-2, oxygen saturation, virus spike protein, thorax, lungs, pulsed magnetic stimulation, SpO<sub>2</sub>, hyperthermia, magnetic therapy, virus inactivation, COVID-19

May 21th 2021

2

46 **Abstract**

47       The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may cause  
48 low oxygen saturation (SpO<sub>2</sub>) and respiratory failure in coronavirus disease (COVID-19)  
49 patients. Hence the increase of SpO<sub>2</sub> levels could be crucial for the quality of life and  
50 recovery of these patients. Here we introduce an electromagnetic device termed low-  
51 field thoracic magnetic stimulation (LF-ThMS) system. This device was designed to non-  
52 invasively deliver a pulsed magnetic field from 100 to 118 Hz and 10.5 to 13.1 mT (i.e.,  
53 105 to 131 Gauss) to the dorsal thorax. We show that these frequencies and magnetic  
54 flux densities are safe for the patients. We also present a proof-of-concept that a single  
55 session of LF-ThMS applied for 30 minutes to the dorsal thorax of 17 COVID-19 patients  
56 significantly increases their SpO<sub>2</sub> levels. We designed a single-blind, sham-controlled,  
57 crossover study on 5 COVID-19 patients who underwent two sessions of the study (real  
58 and sham LF-ThMS) and 12 COVID-19 patients who underwent only the real LF-ThMS.  
59 We found a statistically significant correlation between magnetic flux density, frequency,  
60 or temperature associated with the real LF-ThMS and SpO<sub>2</sub> levels in all COVID-19  
61 patients. However, the five patients of the sham-controlled study did not exhibit a  
62 significant change in their SpO<sub>2</sub> levels during sham stimulation. All the patients did not  
63 present adverse events after the LF-ThMS intervention.

64

65

66

67

68

May 21th 2021

3

## 69 **Introduction**

70           Although recent studies about the structure and function of SARS-CoV-2 may  
71 help develop new targeted treatments against COVID-19, there is still not a universally  
72 approved treatment for this sickness [1,2]. For instance, some pharmacological  
73 treatments include the controversial use of azithromycin, ivermectin, oseltamivir,  
74 remdesivir, favipiravir, tocilizumab, ribavirin, lopinavir, interferon  $\beta$ -1b,  
75 lopinavir/ritonavir, hydroxychloroquine, or chloroquine phosphate (for review, see  
76 [1,3,4]). Many of them are based mainly on case studies, prospective, or retrospective  
77 observational studies, with a low number of randomized controlled trials and low quality  
78 of study design to guarantee their efficacy and safety [5]. Moreover, in severe cases,  
79 many countries employ empiric antimicrobial therapy, mechanical ventilation,  
80 convalescent plasma therapy, or combinations of antiviral and anti-inflammatory drugs  
81 [6,7]. Because fever and acute respiratory failure are common symptoms, the  
82 management of these patients includes antipyretics and oxygen therapy to increase  
83 SpO<sub>2</sub> levels during respiratory distress. Hence the development of new methods to  
84 increase SpO<sub>2</sub> levels in COVID-19 patients could become a potential complement of  
85 oxygen masks, ventilators, or other modalities to improve oxygenation.

86           This study aimed to present a proof-of-concept that a 30 minutes single-session  
87 of dorsal LF-ThMS can be employed to increase SpO<sub>2</sub> levels in COVID-19 patients  
88 significantly. We hypothesized that the variables associated with LF-ThMS, as  
89 frequency, magnetic flux density, and temperature in the dorsal thorax, might be  
90 correlated to SpO<sub>2</sub> levels in these patients. Our proof-of-concept research could be  
91 helpful to design future randomized controlled trials intended to develop plausible LF-  
92 ThMS treatments in the successful management of these patients.

May 21th 2021

4

93 We acknowledge that several magnetic field interventions are controversial, but  
94 others are gaining an excellent reputation as the transcranial magnetic stimulation. This  
95 controversy could be due to the low quality of study designs alongside the exaggerated  
96 promotion of alternative therapies intended only for lucrative practices. Therefore, to  
97 avoid misinterpretations with our research, we included a single-blind, sham-controlled,  
98 crossover study on 5 COVID-19 patients who underwent two sessions of the study (real  
99 and sham LF-ThMS) and 12 COVID-19 patients who underwent only the real LF-ThMS.  
100 Moreover, we applied LF-ThMS in a short time range, i.e., in a 30 minutes single-  
101 intervention to measure SpO<sub>2</sub> values. In this form, we avoided confounding factors  
102 related to the spontaneous recovery by natural immunity, common in many COVID-19  
103 patients several days after the contagion.

104 Regarding safety, our LF-ThMS device applied to the dorsal thorax produces low-  
105 intensity magnetic flux densities in a safe range of 10.5 to 13.1 mT at 100 to 118 Hz.  
106 Such magnetic fields are within the frequency range of extremely low-frequency (0–300  
107 Hz) magnetic fields (ELF-MFs) to study the interaction between ELF-MFs and neuronal  
108 systems [8,9,10]. Our LF-ThMS device also produces heat with a safe temperature  
109 range from 27.5 to 44 °C, consistent with the well-known tolerance of the isolated and  
110 perfused dog lung to hyperthermia in this temperature range [11,12]. Rickaby et al.  
111 (1991) [11] found that temperatures below 44.4 °C for two hours had no detectable  
112 influence on the following measured variables of lung weight, extravascular water,  
113 vascular volume, serotonin uptake, urea permeability, surface area product, perfusion  
114 pressure, and lung compliance. In line with such findings, Cowen et al. (1992) [12]  
115 confirmed that the isolated dog lung with perfusion was tolerant to hyperthermia up to

May 21th 2021

5

116 about 44 °C for 1 hour. Other studies claim that hyperthermia in this range is beneficial  
117 and enhances the immune response [13,14,15].

118 Our results demonstrate that LF-ThMS locally applied to the dorsal thorax of  
119 COVID-19 patients is safe and valuable to significantly increase SpO2 levels during a  
120 single LF-ThMS intervention of 30 minutes. This is in line with models predicting the  
121 electrical [16] or thermal inactivation of SARS-CoV-2 [17] in the environment or with the  
122 hypothesis that hydro-thermotherapy or photobiomodulation could help in the treatment  
123 of COVID-19 patients [18,19].

## 124 **Materials and methods**

### 125 **Study design**

126 We designed a single-blind, sham-controlled, crossover study on 5 COVID-19  
127 subjects who underwent two sessions of the study (sham or real LF-ThMS) and 12  
128 COVID-19 subjects who underwent only the real LF-ThMS stimulation. The study was  
129 performed following the Declaration of Helsinki and approved by a local ethics  
130 committee from the Benemérita Universidad Autónoma de Puebla, Mexico (protocol:  
131 Oficio No. SIEP/C.I./065A/2020, book number: 2, sheet number: 133, registration  
132 number: 818, date: July 3, 2020). The study was registered in ClinicalTrials.gov  
133 (Identifier: NCT04895267). All subjects voluntarily participated with full understanding  
134 and signed informed consent. The SPIRIT-Checklist is included as a supplementary file.

### 135 **Patients**

136 We applied LF-ThMS on the dorsal thorax to 17 patients (25-81 years of age)  
137 who were selected according to the following criteria. The inclusion criteria were: 1)  
138 Adult patients diagnosed with mild to moderate COVID-19 disease without pneumonia.  
139 The COVID-19 disease severity was interpreted by the clinical assessment of

May 21th 2021

6

140 physicians, who followed the interim guidance for the clinical management of COVID-19  
141 from the world health organization, May 27, 2020. 2) Patients with a SpO<sub>2</sub> level less or  
142 equal to 90 %, exhibiting difficulty breathing, but not intubated patients. The physicians  
143 selected this set of patients because they had a low risk of developing a severe clinical  
144 condition with pneumonia or with a chance of being intubated. 3) Patients with similar  
145 pharmacological treatment against COVID-19. All the patients were medicated by  
146 physicians in respiratory medicine with Azithromycin (500 mg), Ivermectin (6 mg), and  
147 Oseltamivir (75 mg). The most prevalent comorbidities in these patients were diabetes  
148 and hypertension.

149 The exclusion criteria were as follows: 1) COVID-19 patients with acute  
150 respiratory failure requiring urgent intubation, 2) COVID-19 patients with impaired  
151 consciousness or during pregnancy, 3) patients with metallic implants in the thorax,  
152 abdomen or arms, or electronic medical devices such as pacemakers, and 4) children.

153 The criteria for discontinuing the LF-ThMS intervention were the participant  
154 request, SpO<sub>2</sub> decrease, or any discomfort reported by the patient during the  
155 intervention. The strategy for achieving adequate participant enrolment to reach target  
156 sample size was the description of favorable results obtained from other patients

### 157 ***Low-field thoracic magnetic stimulation (LF-ThMS) device***

158 Dominguez-Nicolas developed the first custom-designed LF-ThMS device (patent  
159 pending by Dominguez-Nicolas SM, 2020) to modulate alternating current in a coil pair  
160 to generate low magnetic flux densities and magnetic hyperthermia for COVID-19  
161 patients. Previous patents and experimental studies also induce magnetic hyperthermia  
162 [20-23], but they reach up to 71 °C (160 °F), not suitable for our application. Instead, we  
163 employed an electronic circuit in our LF-ThMS device to limit the temperature and

May 21th 2021

7

164 magnetic flux density levels up to 44 °C and 13.1 mT for its safe use in the dorsal thorax  
165 of COVID-19 patients. In this form, we avoided harmfulness or adverse effects. The LF-  
166 ThMS device consisted of a virtual instrument, a PCI-DAS6031 acquisition board  
167 (Measurement Computing), an electronic board for the coupling between the digital  
168 signal and power, a power source of 0-15 Vcc, and 6-30 A, and two rings made of coils  
169 to generate LF-ThMS. We used 1.7 cm of cotton cloth disk between the LF-ThMS rings  
170 and the patient's skin to allow homogeneous heat diffusion.

171 To generate the magnetic field, we used alternating current from 100 to 118 Hz  
172 with a peak amplitude of 8 A, polarized at 12 Vcc with a regulated power source of 0-15  
173 Vcc and 6-30 A. We fabricated a couple of rings for LF-ThMS with an internal diameter  
174 of 9.5 cm and 130 turns. The LF-ThMS device emitted magnetic flux densities in the  
175 range of 10.5 to 13.1 mT. These were calculated theoretically with the Biot-Savart law  
176 and physically with a magnetic field sensor (475 DSP Gaussmeter, Lakeshore). We also  
177 used a thermocouple sensor (model NTC 10k) for monitoring temperature changes due  
178 to the LF-ThMS. Both the Gaussmeter and thermocouple sensors were helpful to  
179 calibrate magnetic flux densities and temperatures in a safe range ([Table 1](#)).

180 The main electronic components of the LF-ThMS device consist of a power relay  
181 RL of two poles, a 12 Vcc coil, silver alloy contacts of Vcc/10A or 250 Vca/10A, Q NPN  
182 2N2222 transistor, 10 kΩ resistance at 0.25 Watts, and a D IN4007 semiconductor  
183 diode. We also employed a PCI-DAS6031 board to energize the RL at 10 Vcc and a  
184 virtual instrument developed in Delphi Borland 7. [Figure 1](#) shows the electronic circuit of  
185 our LF-ThMS device, and [Table 1](#) shows the frequency, magnetic flux density, and  
186 temperature associated with the LF-ThMS during a 30 minutes single session.

May 21th 2021

8

187 ***LF-ThMS protocol***

188         The LF-ThMS was locally applied on the dorsal thorax while the patients were  
189 kept in a prone position. The LF-ThMS intensity was successively increased every 5 min  
190 during a single session of 30 min, following the values of frequency, magnetic flux  
191 density, and temperature indicated in [Table 1](#). The protocol for the proof of concept  
192 consisted of a single LF-ThMS session of 30 minutes, although other daily sessions in  
193 three or four other consecutive days were applied to verify its reproducibility. The  
194 rationale of presenting here only the results from the first session was to evaluate the  
195 hypothesis that SpO<sub>2</sub> levels in COVID-19 patients are significantly correlated with the  
196 magnetic flux density and temperature during 30 minutes of LF-ThMS intervention (see  
197 discussion section).

198         [Figure 2A](#) illustrates anatomical landmarks and coordinates of the LF-ThMS rings.  
199 We positioned the center of these LF-ThMS rings using palpable skeletal landmarks. We  
200 employed the spinous process of C7 (i.e., *vertebra prominens*) as zero landmarks (see a  
201 gray circle in [Figure 2A](#)). The center of these rings was positioned 8.5 cm below this  
202 landmark and bilaterally  $\pm 6$  cm on the dorsal thorax (see black arrows in [Figure 2A](#)).

203         The device allowed a gradual increase in the frequency, magnetic flux density,  
204 and temperature, as illustrated in [Figure 2B, 2C, and 2D](#), respectively. The patients  
205 rested for three hours after the session, and they did not report any discomfort during or  
206 after the magnetic stimuli. In contrast, they felt more comfortable, mainly because the  
207 LF-ThMS improved their breathing from the first minutes of the session. We checked on  
208 the health conditions of all the patients after receiving the LF-ThMS. In addition, in 11/17  
209 patients, we monitored their SpO<sub>2</sub> levels at the end of six months (see Results section).

210

May 21th 2021

9

211 ***Sham stimulation***

212 The coils were positioned in the same coordinates for sham exposure, but the  
213 pulse generator was not turned on. Subjects were blinded for the real LF-ThMS or sham  
214 stimulation conditions.

215 ***Peripheral oxygen saturation (SpO<sub>2</sub>) level, magnetic flux density, and temperature***  
216 ***monitoring***

217 The peripheral oxygen saturation (SpO<sub>2</sub>) level was monitored with a conventional  
218 fingertip pulse oximeter (model C101H1) every 5 minutes during the 30 minutes LF-  
219 ThMS session. Thus, seven SpO<sub>2</sub> measurements, including the control (time zero, at  
220 27.5 °C and 0 mT, without LF-ThMS and compensating the terrestrial magnetic field),  
221 were obtained per subject. In this way, we were able to quantify the repeatability of  
222 effects of LF-ThMS through the study in different patients.

223 ***Statistical analysis***

224 We analyzed the statistical differences among the SpO<sub>2</sub> levels related to each  
225 LF-ThMS intensity. For data normally distributed (Kolmogorov-Smirnov normality test,  
226  $P > 0.05$ ) with homogeneity of variances, we used parametric one-way repeated-  
227 measures ANOVA under the null hypothesis that the dependent variables "SpO<sub>2</sub> levels"  
228 were the same across the different LF-ThMS intensities. We also employed Mauchly's  
229 test to verify that the assumption of sphericity was not violated. We performed a  
230 pairwise post hoc test using the corrected Bonferroni adjustment. All effects are reported  
231 as significant if  $p < 0.001$ .

232 Moreover, a Pearson's product-moment correlation coefficient was employed to  
233 examine whether there is a statistically significant linear correlation between SpO<sub>2</sub>  
234 levels and frequency, magnetic flux density, and temperature changes during the LF-

235 ThMS intervention. The sample size was n=35 SpO<sub>2</sub> measurements during seven LF-  
236 ThMS levels (including the control) in five patients of the sham-controlled experiment  
237 and n=119 SpO<sub>2</sub> values in another 12 patients. The correlation coefficient was  
238 calculated for n-2=33 or n-2=117 degrees of freedom (DF), and the correlation was  
239 reported as significant if p<0.001. Data were expressed as mean ± standard deviation in  
240 the main text and the figures.

## 241 **Results**

242 We measured the SpO<sub>2</sub> level for all the patients before the LF-ThMS intervention.  
243 We found that COVID-19 patients presented similar symptoms. On the first day of  
244 magnetic stimulation, we found that the patients experienced difficulty breathing with a  
245 low SpO<sub>2</sub> level of 86.6 ± 2.2 % (N=17 patients), consistent with COVID-19 signs and  
246 breathlessness symptoms. However, we found that during the LF-ThMS, the patients  
247 exhibited a gradual increase in their SpO<sub>2</sub> levels. No adverse events or discomfort  
248 sensations were reported during or after the LF-ThMS.

### 249 ***Comparisons between the SpO<sub>2</sub> levels of COVID-19 patients in the sham and real*** 250 ***LF-ThMS***

251 In the controlled study, we observed no statistically significant changes in SpO<sub>2</sub>  
252 levels during sham stimulation (five subjects, [Figure 3A](#)). We performed parametric one-  
253 way repeated-measures ANOVA to examine statistical significance between SpO<sub>2</sub>  
254 levels during the sham stimulation in all the patients. The differences in the mean values  
255 among the sham groups are not great enough to exclude the possibility that the  
256 difference is due to random sampling variability, i.e., there is no statistically significant  
257 difference [F=0.165, DF=6, p=0.984].

May 21th 2021

11

258           However, during the real LF-ThMS, we observed statistically significant changes  
259 in SpO2 levels in response to real LF-ThMS in 5 COVID-19 subjects who previously  
260 underwent sham stimulation (green triangles and green line; [Figure 3B](#)) and in the other  
261 12 COVID-19 subjects who underwent only the real LF-ThMS (orange circles and gray  
262 line; [Figure 3B](#)). We performed parametric one-way repeated-measures ANOVA to  
263 examine statistical significance between groups: "control SpO2 levels" and "SpO2 levels  
264 during the LF-ThMS interventions" in all the patients (17 subjects). The differences in the  
265 mean values among the treatment groups were more significant than would be expected  
266 by chance [ $F=13.872$ ,  $DF=6$ ,  $p<0.001$ ]. The post hoc test indicated that the significant  
267 main effect exhibited significant differences ( $p<0.001$ ) between the "control SpO2 levels"  
268 and the "SpO2 levels obtained after 20 min of LF-ThMS interventions" ([Table 2](#)). In  
269 contrast, no statistically significant differences ( $p>0.05$ ) were found before 20 min of LF-  
270 ThMS interventions ([Table 2](#)). This indicates that the LF-ThMS at the frequency and  
271 magnetic flux density employed produces changes in SpO2 levels only after 20 minutes  
272 of LF-ThMS application.

273           ***Correlations among the frequency, magnetic flux density, and temperature elicited***  
274           ***by the LF-ThMS versus the SpO2 levels of COVID -19 patients***

275           In the controlled study, we also examined whether SpO2 levels exhibited  
276 correlations with the sham session time. We observed no statistically significant  
277 correlation between SpO2 levels and session time in the sham condition (Pearson's  
278 product-moment correlation coefficient  $r=0.07$ ,  $DF=33$ ,  $p=0.65$ , gray regression line,  
279 [Figure 3A](#)). However, we obtained a statistically significant correlation between SpO2  
280 values and session time in the real LF-ThMS applied to the same five subjects that

May 21th 2021

12

281 previously underwent the sham stimulation (Pearson's product-moment correlation  
282 coefficient  $r=0.81$ ,  $DF=33$ ,  $p<0.001$ , green regression line, [Figure 3B](#)).

283 Finally, we examined whether the SpO2 levels exhibited correlations with the LF-  
284 ThMS session time, frequency, magnetic flux density, and temperature for all the  
285 patients. [Figure 3B and Figures 4A, 4B, and 4C](#) show significant correlations between  
286 these measurements. Pearson's product-moment correlation method was used to test  
287 for significant correlations. We obtained a  $p<0.001$  with 117 or 100 degrees of freedom  
288 and correlation coefficients  $r = 0.64$ ,  $0.58$ ,  $0.55$ , and  $0.64$ , as indicated (see [Figure 3B](#),  
289 [and Figures 4A, 4B, and 4C](#)). These statistically significant results suggest that the  
290 changes in SpO2 levels during a 30 min LF-ThMS session are related to their  
291 associated variables: frequency, magnetic flux density, and temperature. These findings  
292 provide support to our hypothesis.

### 293 ***Adverse events***

294 We did not find adverse effects during or after the LF-ThMS intervention. We also  
295 made a follow-up on the health conditions of all the patients. We found that five days  
296 after successive LF-ThMS sessions, the mean SpO2 level was  $98.3 \pm 0.7$  % for 17  
297 patients ([Table 3](#)). We also found a mean SpO2 level of  $98.4 \pm 0.8$  %, for 11 patients, six  
298 months after the LF-ThMS intervention ([Table 3](#)). Such normal SpO2 levels indicate that  
299 the LF-ThMS did not produce adverse events in the oxygen saturation. In the follow-up  
300 on the general health conditions after five days or six months, the physicians confirmed  
301 that the patients did not exhibit any adverse event or secondary effect after the LF-  
302 ThMS intervention. These findings indicate that 30 minutes of LF-ThMS intervention on  
303 the dorsal thorax of COVID-19 patients is safe at the frequencies, magnetic flux

May 21th 2021

13

304 densities, and temperatures of 100 to 128 Hz, 10.5 to 13.1 mT, and 27.5 to 44 °C,  
305 respectively.

## 306 **Discussion**

307 We found statistically significant correlations between SpO2 levels in COVID-19  
308 patients and LF-ThMS variables in a time range of 30 minutes, but not in the sham-  
309 controlled study.

### 310 ***Reproducibility***

311 Our findings were reproducible in all the patients in a time range of 30 minutes of  
312 LF-ThMS intervention. Interestingly, our results were also reproducible in three or four  
313 other subsequent sessions. However, we did not present such data because the  
314 changes could be associated with an ongoing daily recovery of the patients due to  
315 unknown immune mechanisms and not necessarily due to the daily LF-ThMS  
316 intervention. Hence, future studies of randomized controlled trials will be necessary to  
317 examine the potential use of this LF-ThMS application as therapy during consecutive  
318 daily sessions in covid-19 patients. Therefore, the principal value of our results is that in  
319 the sham-controlled study, we found a reproducible and significant correlation between  
320 LF-ThMS associated variables and SpO2 levels in a short time range of 30 minutes.

### 321 ***Possible interference of LF-ThMS hyperthermia with the virus-host protein*** 322 ***interactions***

323 It is well known that several viral protein complexes mediate the entry and  
324 replication of SARS-CoV-2 into the cells, manipulating the host mRNA translation,  
325 subsequent viral protein production, antiviral immunity, and inflammation response to  
326 inducing lung infection and pneumonia. Specifically, this pathogen is a single-stranded  
327 RNA virus with gene fragments expressing structural and nonstructural proteins [24-26].

May 21th 2021

14

328 Several viral protein complexes are involved in the entry and replication of this virus into  
329 the cells; for instance, the virus spike (S) protein and the nonstructural protein 1 (nsp1).  
330 The first one mediates cell entry via binding with angiotensin-converting enzyme 2 in  
331 host cells (ACE2), and the second one, the crucial virus-host interactions [27,28].  
332 Because there is evidence that a temperature increase of tissue can affect proteins and  
333 enhance the immune response [14,15], it is tempting to speculate that hyperthermia  
334 produced by the LF-ThMS may acutely interfere with these viral proteins and improve  
335 respiratory function.

336 ***Possible interference of LF-ThMS magnetic flux with the virus-host electrical***  
337 ***interactions***

338 Another possibility is that the magnetic stimuli could also directly interfere with the  
339 positively charged site in the SARS-CoV-2 spike protein, disturbing the electrical binding  
340 between the virus protein and the negatively charged human-cell receptors. This is  
341 consistent with recent simulation studies, reporting a positively charged site (called  
342 polybasic cleavage site) positioned 10 nanometers from the actual binding site on the  
343 SARS-CoV-2 spike protein [29]. These authors found that the positively charged site  
344 allows strong bonding between the virus protein and the negatively charged cell  
345 receptors. In their simulation, Qiao and Olvera de la Cruz [29] designed a negatively  
346 charged molecule to bind to the positively charged cleavage site, with the idea that  
347 blocking this site inhibits the virus from bonding to the host cell [29]. Therefore, it is also  
348 tempting to speculate that interfering with the electrostatic interaction during the binding  
349 action of the SARS-CoV-2 spike protein and the ACE2 receptors, or the nsp1 could  
350 mitigate the viral infection. This possible mode of action of the LF-ThMS is also

May 21th 2021

15

351 consistent with the claim that electrostatic precipitators are also valuable for eliminating  
352 airborne virus particles [30,31].

353 ***Possible interference of LF-ThMS hyperthermia with the immune response and***  
354 ***interferon activity***

355 Another mechanism by which the LF-ThMS up to 44 °C could improve SpO<sub>2</sub>  
356 levels in COVID-19 patients is the enhanced immune response due to the dorsal  
357 thorax's increased temperature during the intervention. This is consistent with reports  
358 that hyperthermia potentiates the immune response against cancer through immune  
359 cells' activation [15,32,33]. Some of the immune cells activated by hyperthermia are the  
360 natural killer cells, dendritic cells, and cytotoxic T-lymphocytes, which alter the cell-  
361 surface molecules on cancer cells, modifying adhesion molecules on immune cells and  
362 endothelial cells [32].

363 Previous studies claimed that Interferons could have a potential role in treating  
364 COVID-19 patients [34]. However, recent investigations demonstrated that the SARS-  
365 CoV-2 receptor ACE2 is an Interferon-stimulated gene in human airway epithelial cells  
366 [35]. This means that interferons could help or damage, depending on the infection  
367 stage for each COVID-19 patient. In this context, we suggest that LF-ThMS should be  
368 applied at the first stages of the COVID-19 infection to enhance interferon activity by an  
369 increased temperature, in which the interferons may confer an antiviral state on cells.

370 ***Possible interference of LF-ThMS in inflammation and cytokine storm***

371 Finally, because the inflammation and cytokine storm are the main factors  
372 contributing to breathing, ventilation, and oxygenation, in COVID-19 patients, it will be  
373 necessary to examine in future studies whether the LF-ThMS has an impact on these  
374 factors.

375 ***Advantages and limitations***

376           The first potential advantage of the thoracic LF-ThMS is that the subjects did not  
377 require oxygen therapy with face masks, mainly because during the LF-ThMS session,  
378 the patients significantly increased their SpO<sub>2</sub> levels 20 minutes after the LF-ThMS  
379 ( $p < 0.001$ , Table 2). The second advantage is that the device for LF-ThMS is easy to  
380 reproduce, and the electronic components are not expensive. It may be possible that  
381 several pulsed electromagnetic field devices employed in physical therapy worldwide  
382 could be adapted to emit magnetic fields at 100 to 118 Hz, 10.5 to 13.1 mT (105 to 131  
383 Gauss), and 27.5 to 44 °C.

384           The main limitations of our study are the following. We do not know the  
385 physiological mechanisms through which the administered LF-ThMS during a 30 min  
386 session improved SpO<sub>2</sub> levels in COVID-19 patients. We also did not explore whether  
387 the LF-ThMS intervention enhances the patients' immune response or whether it  
388 impacts the electrical charges of the SARS-CoV-2 viral proteins or the inflammation and  
389 cytokine storm in COVID-19 patients. However, our study will motivate future  
390 investigations in this research field.

391           Another limitation of our study is that it will be necessary to know the real  
392 temperature in the lungs associated with variations in temperature of the external dorsal  
393 thorax by LF-ThMS. It is expected that such temperatures should be lower than those on  
394 the external dorsal thorax due to the diffusion processes of heat transfer occurring in the  
395 skin, muscle, and scapula. In the same context, it will be necessary to examine the  
396 magnetic flux density reached into the lungs, which should be attenuated as a function  
397 of depth.

398 Finally, while there is a consensus that repetitive magnetic stimulation is helpful in  
399 the non-invasive modulation of brain neural activity in humans, the use of similar  
400 interventions in other regions of the human body is still controversial. Besides such a  
401 limitation, here we found the experimental correlation of LF-ThMS variables: magnetic  
402 flux density, frequency, and temperature with SpO2 levels in 17 COVID-19 patients, five  
403 of them in a single-blind, sham-controlled, crossover study.

#### 404 ***Perspectives***

405 Although the increased SpO2 levels may be attributed to the altered perfusion  
406 consequent to warming or the impact of magnetic factors inactivating the SARS-CoV-2  
407 virus, at this moment, these are only speculations. Therefore, future studies will be  
408 necessary to examine the physiological mechanisms of these significant correlations.

409 Besides previous studies suggest that magnetic stimulation could be helpful in  
410 chronic obstructive pulmonary disease [36] and phrenic nerve activation [37], future  
411 studies examining this issue by using the LF-ThMS in humans or animal preparations  
412 will also be necessary. Other future perspectives include developing wearable and  
413 portable devices for LF-ThMS, combined with oximeters and respiratory magnetograms  
414 [38]. Such devices could help examine in more detail respiratory improvements after the  
415 thoracic LF-ThMS in COVID-19 patients.

416 Here our LF-ThMS protocol is not intended to demonstrate its use as therapy but  
417 is instead designed to examine the hypothesis that LF-ThMS could be helpful to  
418 increase SpO2 levels in COVID-19 patients in a short range from 0 to 30 minutes. In this  
419 context, our findings are relevant because they could motivate future randomized clinical  
420 trials to examine whether the LF-ThMS could be helpful as a potential therapy.

421

May 21th 2021

18

422 **Conclusions**

423 We conclude that our findings are relevant at this stage, mainly because they  
424 provide evidence that 30 minutes of LF-ThMS on the dorsal thorax at 100 to 118 Hz,  
425 10.5 to 13.1 mT (105 to 131 Gauss), and 27.5 to 44 °C is safe in COVID-19 patients. We  
426 also conclude that the LF-ThMS variables (frequency, magnetic flux density, and  
427 temperature) exhibit a statistically significant correlation with SpO2 levels in the time  
428 range of 30 minutes, showing that the LF-ThMS significantly increases peripheral  
429 oxygen saturation levels in COVID-19 patients.

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446 **References**

- 447 1. Babaei F, Mirzababaei M, Nassiri-Asl M, Hosseinzadeh H. Review of registered  
448 clinical trials for the treatment of COVID-19. *Drug Dev Res.* 2020;(ddr.21762).  
449 doi:10.1002/ddr.21762
- 450 2. Haneef K, Asghar MU, Ali A. Novel immunogenomic insights of corona virus  
451 disease (COVID-19): Available potential immunotherapeutics, current challenges,  
452 immune cell recognition and ongoing managerial strategies. *Biomed Res Ther.*  
453 2020;7(8):3906-3915.
- 454 3. Tobaiqy M, Qashqary M, Al-Dahery S, et al. Therapeutic management of patients  
455 with COVID-19: a systematic review. *Infection Prevention in Practice.*  
456 2020;2(3):100061.
- 457 4. Chen P-L, Lee N-Y, Cia C-T, Ko W-C, Hsueh P-R. A review of treatment of  
458 Coronavirus disease 2019 (COVID-19): Therapeutic repurposing and unmet  
459 clinical needs. *Front Pharmacol.* 2020;11:584956.
- 460 5. Daou F, Abou-Sleymane G, Badro DA, Khanafer N, Tobaiqy M, Al Faraj A. The  
461 history, efficacy, and safety of potential therapeutics: A narrative overview of the  
462 complex life of COVID-19. *Int J Environ Res Public Health.* 2021;18(3):955.
- 463 6. Gálvez-Romero JL, Palmeros-Rojas O, Real-Ramírez FA, et al. Cyclosporine A  
464 plus low-dose steroid treatment in COVID-19 improves clinical outcomes in  
465 patients with moderate to severe disease: A pilot study. *J Intern Med.*  
466 2020;(joim.13223). doi:10.1111/joim.13223
- 467 7. Naveja JJ, Madariaga-Mazón A, Flores-Murrieta F, et al. Union is strength: antiviral  
468 and anti-inflammatory drugs for COVID-19. *Drug Discov Today.* 2021;26(1):229-  
469 239.

- 470 8. Di Lazzaro V, Capone F, Apollonio F, et al. A consensus panel review of central  
471 nervous system effects of the exposure to low-intensity extremely low-frequency  
472 magnetic fields. *Brain Stimul.* 2013;6(4):469-476.
- 473 9. Robertson JA, Théberge J, Weller J, Drost DJ, Prato FS, Thomas AW. Low-  
474 frequency pulsed electromagnetic field exposure can alter neuroprocessing in  
475 humans. *J R Soc Interface.* 2010;7(44):467-473.
- 476 10. Cook CM, Thomas AW, Keenlside L, Prato FS. Resting EEG effects during  
477 exposure to a pulsed ELF magnetic field. *Bioelectromagnetics.* 2005;26(5):367-  
478 376.
- 479 11. Rickaby DA, Fehring JF, Johnston MR, Dawson CA. Tolerance of the isolated  
480 perfused lung to hyperthermia. *J Thorac Cardiovasc Surg.* 1991;101(4):732-739.
- 481 12. Cowen ME, Howard RB, Mulvin D, Dawson CA, Johnston MR. Lung tolerance to  
482 hyperthermia by in vivo perfusion. *Eur J Cardiothorac Surg.* 1992;6(4):167-172;  
483 discussion 173.
- 484 13. Cohen M. Turning up the heat on COVID-19: heat as a therapeutic intervention.  
485 *F1000Res.* 2020;9:292.
- 486 14. Dieing A, Ahlers O, Hildebrandt B, et al. The effect of induced hyperthermia on the  
487 immune system. *Prog Brain Res.* 2007;162:137-152.
- 488 15. Peer AJ, Grimm MJ, Zynda ER, Repasky EA. Diverse immune mechanisms may  
489 contribute to the survival benefit seen in cancer patients receiving hyperthermia.  
490 *Immunol Res.* 2010;46(1-3):137-154.
- 491 16. Sen A, Khona D, Ghatak S, et al. Electroceutical fabric lowers zeta potential and  
492 eradicates Coronavirus infectivity upon contact. *ChemRxiv.* Published online 2020.  
493 doi:10.26434/chemrxiv.12307214.v1

May 21th 2021

21

- 494 17. Yap TF, Liu Z, Shveda RA, Preston DJ. A predictive model of the temperature-  
495 dependent inactivation of coronaviruses. *Appl Phys Lett*. 2020;117(6):060601.
- 496 18. Ramirez FE, Sanchez A, Pirskanen AT. Hydrothermotherapy in prevention and  
497 treatment of mild to moderate cases of COVID-19. *Med Hypotheses*.  
498 2021;146(110363):110363.
- 499 19. Sigman SA, Mokmeli S, Monici M, Vetrici MA. A 57-year-old African American man  
500 with severe COVID-19 pneumonia who responded to supportive  
501 photobiomodulation therapy (PBMT): First use of PBMT in COVID-19. *Am J Case*  
502 *Rep*. 2020;21:e926779.
- 503 20. Guibert R, Guibert B. Combined thermotherapy and electrotherapy technique.  
504 1994;number 5,315,994.
- 505 21. Zee J. Heating the Patient: A Promising Approach? *Ann. Oncol*. 2002;13(8):1173–  
506 1184.
- 507 22. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of  
508 cancer. *Lancet Oncol*. 2002;3(8):487-497.
- 509 23. Chang D, Lim M, Goos JACM, et al. Biologically targeted magnetic hyperthermia:  
510 Potential and limitations. *Front Pharmacol*. 2018;9:831.
- 511 24. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel  
512 coronavirus: implications for virus origins and receptor binding. *Lancet*.  
513 2020;395(10224):565-574.
- 514 25. Chan JF-W, Kok K-H, Zhu Z, et al. Genomic characterization of the 2019 novel  
515 human-pathogenic coronavirus isolated from a patient with atypical pneumonia  
516 after visiting Wuhan. *Emerg Microbes Infect*. 2020;9(1):221-236.

May 21th 2021

22

- 517 26. Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and functional properties of  
518 SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.  
519 Acta Pharmacol Sin. 2020;41(9):1141-1149.
- 520 27. Min Y-Q, Mo Q, Wang J, Deng F, Wang H, Ning Y-J. SARS-CoV-2 nsp1:  
521 Bioinformatics, potential structural and functional features, and implications for  
522 drug/vaccine designs. Front Microbiol. 2020;11:587317.
- 523 28. Yuan S, Peng L, Park JJ, et al. Nonstructural protein 1 of SARS-CoV-2 is a potent  
524 pathogenicity factor redirecting host protein synthesis machinery toward viral RNA.  
525 Mol Cell. 2020;80(6):1055-1066.e6.
- 526 29. Qiao B, Olvera de la Cruz M. Enhanced binding of SARS-CoV-2 spike protein to  
527 receptor by distal polybasic cleavage sites. ACS Nano. 2020;14(8):10616-10623.
- 528 30. Kettleson EM, Ramaswami B, Hogan CJ Jr, et al. Airborne virus capture and  
529 inactivation by an electrostatic particle collector. Environ Sci Technol.  
530 2009;43(15):5940-5946.
- 531 31. Leung WWF, Sun Q. Electrostatic charged nanofiber filter for filtering airborne  
532 novel coronavirus (COVID-19) and nano-aerosols. Sep Purif Technol.  
533 2020;250(116886):116886.
- 534 32. Terunuma H. Potentiating Immune System by Hyperthermia. In: Hyperthermic  
535 Oncology from Bench to Bedside. Springer Singapore; 2016:127-135.
- 536 33. Tydings C, Sharma KV, Kim A, Yarmolenko PS. Emerging hyperthermia  
537 applications for pediatric oncology. Adv Drug Deliv Rev. 2020;163-164:157-167.
- 538 34. Haji Abdolvahab M, Moradi-Kalbolandi S, Zarei M, Bose D, Majidzadeh-A K,  
539 Farahmand L. Potential role of interferons in treating COVID-19 patients. Int  
540 Immunopharmacol. 2021;90(107171):107171.

- 541 35. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an  
542 interferon-stimulated gene in human airway epithelial cells and is detected in  
543 specific cell subsets across tissues. *Cell*. 2020;181(5):1016-1035.e19.
- 544 36. Man WD-C. Magnetic stimulation for the measurement of respiratory and skeletal  
545 muscle function. *Eur Respir J*. 2004;24(5):846-860.
- 546 37. Similowski T, Fleury B, Launois S, Cathala HP, Bouche P, Derenne JP. Cervical  
547 magnetic stimulation: a new painless method for bilateral phrenic nerve stimulation  
548 in conscious humans. *J Appl Physiol*. 1989;67(4):1311-1318.
- 549 38. Dominguez-Nicolas SM, Juarez-Aguirre R, Herrera-May AL, et al. Respiratory  
550 magnetogram detected with a MEMS device. *Int J Med Sci*. 2013;10(11):1445-  
551 1450.
- 552
- 553
- 554
- 555
- 556
- 557
- 558
- 559
- 560
- 561
- 562
- 563
- 564

565 **Figure legends**

566 **Figure 1.** Electronic circuit employed in the low-field thoracic magnetic stimulation (LF-  
567 ThMS) device. This electronic circuit modulates the intensity and frequency of the  
568 alternating current producing the magnetic fields, limiting the maximum temperature to  
569 44 °C, and the magnetic flux density up to 13.1 mT at 118 Hz.

570 **Figure 2.** Experimental arrangement. **A.** Anatomical landmarks for the positioning of the  
571 LF-ThMS coils in the dorsal thorax of COVID-19 patients. The gray circle indicates the  
572 anatomical landmark called the "spinous process of C7" or "*vertebra prominens*". **B-D.**  
573 Gradual increase (every 5 min) from 0 to 30 minutes of pulsed stimulus frequency,  
574 magnetic flux density, and temperature during the application of LF-ThMS to COVID-19  
575 patients. The stimulation consisted of applying LF-ThMS for 30 minutes on the dorsal  
576 aspect of the thorax.

577 **Figure 3.** Comparative results obtained from the sham-controlled study and the real LF-  
578 ThMS intervention. **A.** Peripheral oxygen saturation (SpO<sub>2</sub>) levels versus time during the  
579 sham stimulation for five COVID-19 patients. Blue circles represent the grand average of  
580 these SpO<sub>2</sub> levels **B.** SpO<sub>2</sub> levels versus time during the LF-ThSM stimulation. The  
581 green triangles represent the grand average of SpO<sub>2</sub> values during the real LF-ThSM in  
582 the same five patients that received sham stimulation in A. The orange symbols illustrate  
583 the grand average SpO<sub>2</sub> levels in 12 COVID-19 patients versus time during a single  
584 session of LF-ThMS. The green and gray circles (raw data) show the SpO<sub>2</sub> values  
585 obtained for all the patients (every 5 minutes) versus the time in minutes. A statistically  
586 significant correlation ( $p < 0.001$ , Pearson's product-moment correlation) was found for  
587 "SpO<sub>2</sub> values" versus "stimulation time" during real LF-ThMS but not during sham  
588 stimulation.

May 21th 2021

25

589 **Figure 4.** The same as Figure 3B, but for the correlation between SpO2 levels and the  
590 variables related to the real LF-ThMS applied to 17 COVID-19 patients. The Pearson's  
591 correlation coefficients (r), degrees of freedom (DF), and p values ( $p < 0.001$ ) are shown  
592 above each graph.

### 593 **Tables**

594 **Table 1.** Variables associated with the LF-ThMS (frequency, magnetic flux density,  
595 temperature) and the mean SpO2 levels in 17 COVID-19 patients.

596 **Table 2.** One way repeated measures ANOVA for the SpO2 values of 17 COVID-19  
597 patients in control conditions (0 minutes) and during the LF-ThMS at 10, 15, 20, 25, and  
598 30 minutes. The Bonferroni t-test was used for multiple comparisons versus the control  
599 group.

600 **Table 3.** Follow-up on the SpO2 values for all the patients after the LF-ThMS. Six  
601 months after the LF-ThMS intervention, the patients reported no adverse events, and  
602 they exhibited normal SpO2 levels.

603

604

605

606

607

608

609

610

611

612


May 21th 2021

26

613

614

615



616

617

618

619

620

621

622

623

624


625

Figure 1

626

627

628



629

630

631

632

633


634

Figure 2

635

636

637



638

639

640

641

Figure 3

642

643

644

645

646

647


648

649

650

651

652



653

654

Figure 4

May 21th 2021

30

655

656

657

<b>Time (min)</b>	<b>Frequency (Hz)</b>	<b>Magnetic flux density (mT)</b>	<b>Temperature °C</b>	<b>SpO2 (%) mean±SD</b>	<b>Number of patients</b>
0	0	0	27.5±0.2	86.6±2.2	17
5	100	10.5±0.01	29.3±0.07	86.7±2.0	17
10	103	10.7±0.04	35.2±0.08	88.0±2.1	17
15	105	11.1±0.12	41.4±0.3	88.8±2.2	17
20	110	11.6±0.02	43.3±0.2	90.1±2.4	17
25	115	12.2±0.2	44±0.05	91.4±2.5	17
30	118	13.1±0.15	43.9±0.01	92.2±3.2	17

658

659

**Table 1**

660

661

662

663

664

665

666

667

668

669

670

671

672

May 21th 2021

31

673

674

675

Comparison	Diff of Means	t	P	Significance
SpO2 (0 min) vs. SpO2 (30 min)	5.588	6.655	<0.001	Yes
SpO2 (0 min) vs. SpO2 (25 min)	4.824	5.745	<0.001	Yes
SpO2 (0 min) vs. SpO2 (20 min)	3.529	4.203	<0.001	Yes
SpO2 (0 min) vs. SpO2 (15 min)	2.176	2.592	0.065	No
SpO2 (0 min) vs. SpO2 (10 min)	1.353	1.611	0.66	No
SpO2 (0 min) vs. SpO2 (5 min)	0.118	0.14	1	No

676

677

678

**Table 2**

679

680

681

682

683

684

685

686

687

688

689

690

May 21th 2021

32

691

692

693

	Before LF-ThMS	30 minutes after Sham Stimulus	30 minutes after LF-ThMS	Five days after LF-ThMS	Six months after LF-ThMS
Patients	SpO2 (%)	SpO2 (%)	SpO2 (%)	SpO2 (%)	SpO2 (%)
Patient 1	88	—	98	98	99
Patient 2	86	—	97	98	97
Patient 3	89	—	96	98	97
Patient 4	90	—	97	99	99
Patient 5	87	—	91	98	99
Patient 6	90	—	93	99	99
Patient 7	87	—	91	97	98
Patient 8	88	—	93	98	98
Patient 9	87	—	91	99	99
Patient 10	86	—	90	98	99
Patient 11	84	—	88	97	99
Patient 12	83	—	86	99	—
Patient 13	84	85	93	99	—
Patient 14	85	86	90	99	—
Patient 15	88	88	93	99	—
Patient 16	83	83	90	98	—
Patient 17	88	88	91	99	—
	86.6 ± 2.2	86 ± 2.1	92.2 ± 3.2	98.3 ± 0.7	98.4 ± 0.8

694

695

696

**Table 3**

697

698

699

700

701

702

May 21th 2021

33

703 **Ethics and reporting**

704 We declare that all relevant ethical guidelines have been followed and ethics committee  
705 approval has been obtained. All necessary patient/participant consent has been  
706 obtained. SPIRIT-Checklist was included as a supplementary file.

707 **Acknowledgments**

708 We thank Prof. Robert Simpson for proofreading the English document.

709 **Data Availability Statement**

710 The authors confirm that all data underlying the findings are fully available without  
711 restriction upon request. All relevant data are within the paper.

712 **Author contributions**

713 SMDN conceived the therapeutic application of magnetic stimuli in COVID-19 patients,  
714 developed the first LF-ThMS prototype, and performed the experiments. EM and SMDN  
715 conceived the proof-of-concept and hypothesis of this study. EM performed the data  
716 analysis. EM designed the single-blind, sham-controlled, crossover study on 5 COVID-  
717 19 patients, wrote the paper, and contributed to calibrate and improve the safeness of  
718 the original LF-ThMS prototype.

719 **Funding**

720 Centro de Investigación de Micro y Nanotecnología (SMDN), National Council of  
721 Science and Technology, Mexico, CONACyT Fronteras de la Ciencia #536 (EM),  
722 Cátedra Marcos Moshinsky (EM), and VIEP-PIFI-FOMES-PROMEPE-BUAP-Puebla  
723 (EM), Comité de Internacionalización and VIEP BUAP (EM), México.

724 **Conflict of Interest**

725 The authors declare that the research was conducted in the absence of any commercial  
726 or financial relationships that could be construed as a potential conflict of interest.